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Theactivation ofnuclear factor kappa B (NF-jB) p50/RelA is a key event inischemic neuronal injury, aswell asin brain ischemic
tolerance. We tested whether epigenetic mechanisms affecting the acetylation state of RelA might discriminate between
neuroprotective and neurotoxic activation of NF-jB during ischemia. NF-jB activation and RelA acetylation were investigated in
cortices of mice subjected to preconditioning brain ischemia or lethal middle cerebral artery occlusion (MCAO) and primary
cortical neurons exposed to preconditioning or lethal oxygen-glucose deprivation (OGD). In mice subjected to MCAO and in
cortical neurons exposed to lethal OGD, activated RelA displayed a high level of Lys310 acetylation in spite of reduced total
acetylation. Also, acetylated RelA on Lys310 interacted strongly with the CREB-binding protein (CBP). Conversely, RelA
activated during preconditioning ischemia appeared deacetylated on Lys310. Overexpressing RelA increased Bim promoter
activity and neuronal cell death both induced by lethal OGD, whereas overexpressing the acetylation-resistant RelA-K310R,
carrying a mutation from Lys310 to arginine, prevented both responses. Pharmacological manipulation of Lys310 acetylation by
thesirtuin1activatorresveratrolrepressedtheactivityoftheBimpromoterandreducedtheneuronalcellloss.Weconcludethat
the acetylation of RelA in Lys310 dictates NF-jB-dependent pro-apoptotic responses and represents a suitable target to dissect
pathological from neuroprotective NF-jB activation in brain ischemia.
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Brainischemiaisaleadingcauseofmortalityandneurological
disability. During brain ischemia, nuclear factor kappa B
(NF-kB) rapidly activates in neurons and glial cells, where it
regulates inﬂammatory and apoptotic events characterizing
the pathophysiology of post-ischemic injury.
1–4 NF-kB activa-
tion in neurons, rather than in glial cells, has a prominent role
in post-ischemic cell loss.
4,5 NF-kB is a dimeric transcription
factor created by the association of different subunits: p50,
p65/RelA, p52, RelB and c-Rel. The most prevalent activated
dimer observed after occlusion of the middle cerebral artery
(MCAO) is p50/RelA.
6,7 Accordingly, the MCAO-induced
infarct size is reduced in p50 knockout mice,
2 as well as in
mice carrying a brain-conditional deletion of RelA.
7 We
showed that activation of the p50/RelA dimer is associated
with inhibition of c-Rel-containing dimers in ischemic brain
tissues and in primary cortical neurons exposed to oxygen-
glucose deprivation (OGD).
8 Selective targeting of c-Rel and
RelA revealed that activation of c-Rel-containing dimers
increases cell resistance to OGD, whereas activation of
p50/RelA contributes to the cell-death program. The effect of
c-Reldimersreliesonpromoteractivationoftheanti-apoptotic
Bcl-xLgene
8andmediatesneuroprotectioninducedbyleptin
9
or agonists at metabotropic glutamate receptor type 5.
10 The
deleterious effect of p50/RelA in brain ischemia depends on
RelA-induced expression of pro-apoptotic Bim and Noxa
genes.
7,8 However, p50/RelA is also involved in the regulation
of a variety of physiological processes. Its constitutive activity
is required for brain neuron survival and neurite elongation
during brain development.
11,12 In mature neurons, p50/RelA
selectively localizes at the synaptic level, from which point it
moves to the nucleus to transmute synaptic signals into
altered gene expression, regulation of synaptic plasticity and
memory formation.
13–15 Furthermore, the activation of p50/
RelA has a role in brain tolerance, the adaptive response
induced by a sublethal insult, which preserves brain health
against subsequent lethal injury.
16 Thus, the opposing effects
elicited by NF-kB activation in cell survival remain to be
elucidated. Recent studies in tumor and peripheral cells have
revealed the post-translational regulation of RelA, including
reversible phosphorylation and acetylation,
17 which modulate
p50/RelA transcriptional activity on target genes.
18 RelA is
acetylated after cell activation by tumor necrosis factor-a,
phorbol myristate acetate or other stimuli. RelA acetylation
may occur at multiple sites, including lysines (Lys) 122, 123,
Received 05.8.10; revised 10.9.10; accepted 16.9.10; Edited by A Verkhrasky
1DivisionofPharmacology andExperimentalTherapeutics, DepartmentofBiomedicalSciences&Biotechnologies,School ofMedicine, UniversityofBresciaandIstituto
Nazionale di Neuroscienze Brescia, Brescia, Italy;
2Department of Obstetrics and Gynecology and Biomedical Technologies, University of Brescia, Brescia, Italy;
3Department of Pharmacology, University of Florence, Florence, Italy and
4Istituto Ricovero e Cura a Carattere Scientiﬁco, S. Camillo Hospital, Venice, Italy
*Corresponding author: M Pizzi, Division of Pharmacology, Department of Biomedical Sciences & Biotechnologies, Viale Europa, 11, Brescia 25123, Italy.
Tel: þ39 030 371 7501; Fax: þ39 030 371 7529; E-mail: pizzi@med.unibs.it
Keywords: RelA acetylation; MCAO; OGD; ischemic preconditioning
Abbreviations: BCCAO, bilateral common carotid arteries occluded; CBP, p300/CREB-binding protein; DIV, days in vitro; FOXO3a, Forkhead transcription factors;
IPC, ischemic preconditioning; JNK, c-Jun N-terminal protein kinase; LDH, lactate dehydrogenase; Lys, lysine; MCAO, occlusion of middle cerebral artery; NF-kB,
nuclear factor kappa B; OGD, oxygen-glucose deprivation; RA, retinoic acid; SIRT1, sirtuin 1
Citation: Cell Death and Disease (2010) 1, e96; doi:10.1038/cddis.2010.76
& 2010 Macmillan Publishers Limited All rights reserved 2041-4889/10
www.nature.com/cddis218, 221 and 310.
17 The epigenetic regulators of histone
proteins, acetyltransferases p300/CREB-binding protein
(CBP) and p/CAF, appear to have a major role in the in vivo
acetylation of RelA.
19 Site-speciﬁc acetylation of RelA
regulates discrete biological actions of the NF-kB complex.
For example, acetylation of Lys218 and 221 increases the
DNA binding afﬁnity of RelA for the kB enhancer and impairs
RelA assembly with newly synthesized IkBa,
19 whereas
acetylation of RelA at Lys122 and 123 inhibits its transcrip-
tionalactivity.
17AcetylationofLys310doesnotmodulateDNA
binding or IkBa assembly, but markedly enhances the NF-kB
transactivation of pro-inﬂammatory genes. Acetylation of
Lys310 is required for the full transcriptional activity of RelA.
Abolishing Lys310 acetylation by mutating Lys310 to arginine
signiﬁcantly inhibits the transactivation of NF-kB and the
expression of inﬂammatory cytokines,
19,20 possibly by
stabilizing Set-9 factor, which leads to the methylation
of Lys314-315 and proteasomal degradation of RelA.
21
Selective deacetylation of Lys310 by sirtuin 1 (SIRT1), a
class III histone deacetylase, inhibits the transcriptional
activity of RelA
22 and prevents the b-amyloid-induced release
of neurotoxic factors from microglial cells.
23 However, the role
of RelA acetylation in NF-kB-mediated neuronal injury during
brain ischemia remains elusive.
We investigated changes in c-Rel activation and RelA
acetylation in response to preconditioning or lethal ischemia
and the role of these changes in ischemia-mediated gene
transcription and neuronal cell death.
Results
Neuronal activation of NF-jB p50/RelA in preconditioning
and lethal ischemia. It has been shown that as an early
response to ischemic brain injury, NF-kB p50 and RelA
rapidly activate and drive post-ischemic neuronal apoptosis.
4,5,7,8 We previously showed that in primary mouse cortical
neurons exposed to OGD apoptosis precedes necrosis, as
indicated by the early TUNEL-positivity displayed by the
cells within 6h after the OGD and the parallel release
of cytochrome c in the cytosol in absence of lactate
dehydrogenase (LDH) release. Subsequent necrosis
causes progressive elevation of extracellular LDH level that
becomes clearly detectable in the medium 24h after the
OGD exposure.
8 Thus, we here measured delayed LDH level
as a ﬁnal marker of cell death. Either in primary cortical
neurons or in mouse ischemic cortices, enhanced activation
of p50/RelA correlates with the diminished activation of RelA/
c-Rel, an event that contributes to neuronal vulnerability.
In order to analyze and compare the NF-kB dimers induced
by preconditioning or lethal OGD, we set up an ischemic
preconditioning (IPC) model by exposing the cortical neurons
to 1h OGD and, the next day, to 3h OGD. The 1h OGD
condition did not affect cell viability per se and completely
abolished the cell death induced by longer OGD applied 24h
later (Figure 1a). Enzyme-linked immunosorbent assay
(ELISA) analysis of NF-kB showed similar increases
in RelA and p50 DNA-binding activity in nuclear extracts of
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Figure 1 (a) Primary cortical neurons were exposed to 1h OGD and then 24h later to 3h OGD. The next day, cell viability was measured by LDH assay. Sub-lethal
ischemic injury totally prevented the 3h OGD-mediated neurotoxicity. Bars are means±S.E.M. of three separate experiments run in triplicate; *Po0.01 versus the
corresponding control value. (b) Activation of p50 and RelA was evaluated by ELISA analysis in nuclear extracts from cortical cells exposed to 1 or 3h OGD. Bars are
means±S.E.M. of three separate experiments;*Po0.05 versusthe corresponding control value. (c) Representative picture of co-immunoprecipitation analysis of p50, RelA
and c-Rel dimers in nuclear extracts from primary cortical neurons showed a high level of p50/RelA complex activation after 1 or 3h OGD, whereas the activation of c-Rel
dimers decreased slightly
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Cell Death and Diseasecells exposed to 1 and 3h OGD (Figure 1b). The co-
immunoprecipitation analysis of heterodimers composed of
p50, RelA and c-Rel revealed superimposable increases in
levels of p50/RelA under both conditions. No increase was
evident in the levels of p50/c-Rel and RelA/c-Rel complexes
(Figure 1c). These results indicate that p50/RelA, but not
c-Rel dimers contribute to NF-kB activation in cells exposed
to preconditioning, as well as lethal OGD.
RelA acetylation and interaction with CBP differentiate
p50/RelA activation in neuronal cells during lethal as
opposed to preconditioning ischemia. We checked the
possibility of diverse RelA acetylation in two ischemic
conditions, 1 and 3h OGD. RelA was immunoprecipitated
from nuclear extracts and its acetylation was checked using a
speciﬁc anti-Acetyl-RelA Lys310 antibody (RelA Ac-K310) in
comparison with an anti-Acetyl-Lys antibody recognizing
general RelA acetylation. We observed that acetylation
at Lys310 was reduced after 1h OGD but increased
signiﬁcantly after 3h OGD, in spite of reduced levels
of overall RelA acetylation (Figure 2a and b). The diverse
acetylation states of RelA correlated with diverse levels of
interaction with the histone acetyl transferase CBP. RelA
showed higher association with CBP after lethal OGD, but
not after preconditioning ODG (Figure 2a and b). Similar
results were obtained in an in vivo mouse model of brain
ischemia and IPC.
24 Mice were exposed to diverse ischemic
insults: (i) 5min bilateral common carotid arteries were
occluded (BCCAO) (preconditioning ischemia); (ii) 20min
MCAO; and (iii) IPC, that is, BCCAO followed by MCAO the
next day. Ischemic areas (Figure 3a) and infarct volumes
(Figure 3b) were evaluated 3 days later. BCCAO induced no
brain damage, but it signiﬁcantly reduced the ischemic
volume in mice subjected to MCAO (Figure 3b). We tested
RelA acetylation in cortical nuclear extracts prepared 4h
after mice were exposed to the various conditions
(Figure 3c). Higher RelA activation was evident in BCCAO,
MCAO and IPC extracts, but acetylation at Lys310 increased
only in mice exposed to MCAO. Concomitantly with Lys310
acetylation, RelA also displayed higher interaction with CBP
in the MCAO extracts (Figure 3c and d). These results show
that RelA acetylation on Lys310 discriminates between RelA
activation after neurotoxic ischemia and that induced
by preconditioning ischemia.
Acetylation of RelA on Lys 310 is required for toxic
effects elicited by NF-jB activation. The relevance of
RelA acetylation on Lys310 in the NF-kB-mediated neuro-
toxicity after acute ischemic injury was initially investigated in
neuronally differentiated SK-N-SH cells. Under exposure to
retinoic acid (RA), SK-N-SH neuroblastoma cells switch from
a non-neuronal to a neuronal-like phenotype
25 and express
vulnerability to OGD by NF-kB RelA activation.
8 Neuronal
cells were exposed to OGD for 1, 2 and 4h. Western blot
analysis of nuclear extracts conﬁrmed increased acetylation
of RelA on Lys310 after 4h ODG, as observed in primary
cortical neurons (Figure 4a). The neuronal cultures were
transiently transfected with control empty vector (pSG5) or
with expression plasmids coding for human wild-type RelA
or RelA carrying a mutation from Lys310 to arginine
(RelA-K310R). As arginine has the same polar side chain
and charge as lysine but cannot be acetylated, this mutated
form of RelA was used as a negative control to test the
biological effects of speciﬁc Lys310 acetylation.
19 Around
24h after transfection, the nuclear translocation of RelA and
its acetylation were veriﬁed by immunoblot analysis in
nuclear extracts of cells exposed to 4h OGD. We found
that OGD promoted a marked upregulation of nuclear RelA in
cells transfected with empty vector, as well as in cells
overexpressing wild-type RelA or RelA-K310R (Figure 4b
and c). As expected, the concomitant increase in acetylation
on Lys310 after OGD was evident in control and RelA-
overexpressing cells, but negligible in the RelA-K310R-
transfected cells (Figure 4b and c). In order to test the
possibility that this unique modiﬁcation was speciﬁcally
responsible for the regulation of neuronal injury, transfected
cells were exposed to OGD for 15h and cell viability
was measured by LDH release in the medium 24h later.
Cells transfected with the empty vector were vulnerable to
OGD and the overexpression of wild-type RelA signiﬁcantly
increased cell death (Figure 4d), in line with previous
ﬁndings.
8 Instead, the RelA-induced enhancement of
OGD-mediated neurotoxicity was completely abolished in
cells overexpressing the RelA-K310R mutant construct.
Similar experimental conditions were used to analyze the
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Figure 2 (a) Immunoprecipitation analysis of RelA acetylation and association
with CBP in nuclear extracts of primary cortical neurons exposed to 1 or 3h OGD.
RelA Lys310 acetylation decreased after 1h OGD and increased after
3h OGD. Total RelA acetylation was not altered by 1h OGD but was reduced by
3hOGD.RelAassociationwithCBPincreasedinnuclearextractsofcellssubjected
to 3h OGD. The signal given by IgG(H) was used as a control for the quality of the
immunoprecipitation. Similar results were obtained in at least four separate
experiments. (b) Values from densitometric analysis of immunoblot bands are
expressed as a percentage of the corresponding control value. Error bars depict
means±S.E.M.; *Po0.05 versus control
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Cell Death and DiseaseNF-kB-dependent activation of mouse Bim promoter-
luciferase plasmid in cortical neurons during 3h OGD
followed by 4h recovery, a time during which neurons
express Bim and undergo apoptosis.
7,8 We previously
showed that OGD induces the activity of the Bim promoter
but not the activity of BimDkB plasmid carrying a mutation at
the kB site, demonstrating that Bim transcription during OGD
is NF-kB speciﬁc.
8 The OGD-induced Bim promoter was
signiﬁcantly enhanced by RelA overexpression, but fell to
basal levels in cells overexpressing RelA-K310R (Figure 4e).
These results show that NF-kB-mediated Bim transcription is
completely dependent on Lys310 acetylation of RelA. This
mechanism is pivotal in driving the deleterious effects of NF-
kB activation during lethal ischemia.
Resveratrol-mediated neuroprotection is associated
with inhibition of RelA acetylation at the Lys310
residue as well as with the inhibition of Bim promoter
activity. Deacetylation of Lys310 by the class III histone
deacetylase SIRT1 inhibits the transcriptional activity of
RelA.
22 To determine whether pharmacological manipulation
of RelA acetylation could repress NF-kB-mediated
pro-apoptotic transcription during OGD, we tested the
SIRT1-activating molecule resveratrol. Cortical neurons
were exposed to OGD for 3h and then treated for 24h with
resveratrol (1, 3 and 30mM). Even when added during the
post-ischemic period, resveratrol showed signiﬁcant
neuroprotective activity at a concentration of 30mM
(Figure 5a). Immunoprecipitation analysis of RelA in
nuclear extracts conﬁrmed that after OGD, the acetylation
of Lys310 increased and total acetylation decreased.
Treatment with 30mM resveratrol for 2h after OGD only
partially reduced RelA activation, weakly affected general
RelA acetylation and completely deacetylated the Lys310
residue (Figure 5b). In line with this drastic effect on Lys310
acetylation, resveratrol repressed the Bim promoter
activity to levels below the baseline (Figure 5c). These
results represent further evidence that during ischemia, the
neurotoxic activation of NF-kB is associated with RelA
acetylation at Lys310. Drugs that deacetylate RelA at
Lys310, similar to the actions of resveratrol, can block
post-ischemic transcription and neurodegeneration.
Discussion
Here,wereportthatalthoughactivationofNF-kBc-Reldimers
promotes neuronal resistance to environmental noxae,
8–10
NF-kB activation following preconditioning OGD does not
involve c-Rel-containing dimers. Moreover, the p50/RelA
complex is activated in preconditioning, as well as in lethal
OGD. The aberrant activation of p50/RelA dimer in neuronal
cells, responsible for pro-apoptotic events in the post-
ischemic period,
6–8 is characterized by RelA acetylation at
the Lys310 residue. It is unknown whether the acetylation of
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Cell Death and Diseaseother lysine residues is also involved, though the increase
of Lys310 acetylation occurred in spite of decreased total
RelA acetylation. Moreover, acetylation of RelA on Lys310
differentiated the p50/RelA activation during lethal ischemia
from that induced by preconditioning ischemia. The level of
acetylation in Lys310 during OGD paralleled the increased
interaction of RelA with CBP, in line with evidence that RelA
acetylation on Lys310 is strictly dependent on the histone
acetyltransferase activity of CBP/p300.
19 Similar results were
obtained in a model of in vivo brain ischemia and IPC. RelA is
highly activated in cortices of mice exposed to either BCCAO
or MCAO, as previously shown.
16 Notably, the nuclear RelA
level was high also in mice exposed to 1-day IPC, that is,
BCCAO followed by MCAO on the next day. This result is
in contrast to what was observed in models of 3-day IPC, in
which severe ischemia induced 3 days after sublethal
ischemia elicited weaker NF-kB activation as a consequence
of enhanced IkBa expression during the 3-day interval.
16 Our
data support the idea that brain tolerance does not impair
NF-kB translocation, but does affect RelA acetylation and
transactivation. Thus, compared with BCCAO or IPC mice,
the MCAO mice displayed a higher level of Lys310acetylation
that correlated with increased interaction of RelA with CBP.
To elucidate the relevance of Lys310 acetylation to
RelA-mediated effects during ischemia, we transfected the
neuronally differentiated SK-N-SH cells that were displaying
RelA-dependent vulnerability to OGD
8 with the RelA-K310R
mutant construct. We found that OGD greatly enhanced
Lys310 acetylation in control cells, as well as in cells
transfected with RelA, whereas acetylation did not increase
in cells overexpressing RelA-K310R. This result conﬁrmed
that the mutation of lysine to arginine in the RelA sequence
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Figure 4 (a) Immunoblot analysis of nuclear extracts from differentiated SK-N-SH cells exposed to 1–4h OGD. RelA Lys310 acetylation signiﬁcantly increased after 4h
OGD. (b) Neuronal SK-N-SH cells were transfected with wild-type RelA and RelA-K310R plasmids or with a pSG5 empty vector for 24h and then exposed to OGD for 4h.
The OGD-induced RelA acetylation on Lys310 was signiﬁcantly reduced in RelA-K310R expressing cells. (c) Data from densitometric analysis of RelA and RelA Ac-K310
immunoblots are expressed as ratios to relative nucleolin levels. Bars are the means±S.E.M. of three separate experiments; *Po0.05 versus corresponding control value.
(d) Cell survival was measured in SK-N-SH cells exposed to 15h OGD. RelA overexpression signiﬁcantly enhanced OGD toxicity, whereas RelA Ac-K310R overexpression
prevented cell loss. Bars are the means±S.E.M. of three separate experiments; *Po0.01 versus OGD in pSG5-expressing cells. (e) Primary cortical neurons were
transfectedwithBimluciferasereporterplasmidtogetherwithwild-typeRelAorRelA-K310RplasmidsorpSG5emptyvectorfor24handthenexposedto3hOGD.Luciferase
activity was measured after 4h. RelA overexpression enhanced OGD-induced Bim promoter activity, whereas RelA-K310R overexpression totally inhibited such activity.
Bars are the means±S.E.M. of three experiments run in triplicate; *Po0.01, **Po0.05 versus OGD value in pSG5-expressing neurons
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Cell Death and Diseaseimpairs acetylation of the RelA 310 residue.
19 Thus, OGD-
mediated cell death was enhanced in RelA-overexpressing
cells,
8 but was completely impaired in RelA-K310R-trans-
fected cultures. The occurrence of cell death at levels
even lower than those observed in cells expressing
empty vector suggests that deacetylated RelA-K310R
can compete with native Acetyl-RelA Lys310 to maximally
reduce neuronal vulnerability, as observed in the pre-
conditioned cells.
NF-kB ﬁne-tunes cell survival by regulating transcription of
Bcl2 family genes endowed with either anti-apoptotic activity,
as the Bcl-xL, or pro-apoptotic activity, as the BH3-only
members Bim and Noxa.
26 It has been shown that Bim and
Noxa genes, being under the transcriptional control of RelA,
are signiﬁcantly induced 6h after MCAO and their upregula-
tion is abolished in mice carrying a brain-conditional deletion
of RelA.
7 Evidence that cortical neurons exposed to lethal
OGD display NF-kB-dependent induction of Bim, but not
Bcl-xL promoter, highlights the transcriptional speciﬁcity of
p50/RelA activation during anoxic injury.
8 Bim, similar to other
BH3-only proteins, contributes to increase the mitochondrial
permeability and activation of caspase cascade by directly
activating pro-apoptotic Bax and Bak
27 or by releasing
Bax and Bak from their complexes with pro-survival Bcl-2
homologs.
28,29 Bim represents a converging point of diverse
pro-apoptotic pathways during brain ischemia. In addition to
NF-kB, Bim can be transcriptionally induced by Forkhead
transcription factors (FOXO)3a as downstream target of the
PTEN–Akt–FOXO3a pathway activated in ischemic brains.
30
TheinteractionofBimwiththec-JunN-terminalproteinkinase
(JNK), enhances Bim afﬁnity to Bax and increases both
proteins translocation to the mitochondria.
31,32 Intriguingly,
JNK and FOXO3a signaling can be negatively modulated by
the crosstalk with NF-kB in pro-survival pathways
33,34 raising
additional queries about the mode of Bim regulation by NF-kB
in brain ischemia. Here, we show that Bim transcription
during OGD strictly depends on Lys310 acetylation of RelA.
Bim transcription increased during OGD, it was enhanced in
cortical neurons overexpressing RelA, but was completely
inhibited in RelA-K310R-expressing cells. This result
suggests that RelA acetylation on Lys310, through the
recruitment of the coactivator CBP/p300, is a mechanism
evolved to regulate inducible pro-apoptotic genes during
ischemia in neuronal cells. Notably, the transactivation
potential of c-Rel was reported not to be inﬂuenced by the
CBP/p300 interaction.
35 This difference may also account for
diverse regulation of NF-kB target genes by c-Rel and RelA
during ischemia.
8 The speciﬁc RelA acetylation on Lys310
representsamoleculartargettomodifygenetranscriptionand
neuronal resilience to ischemic injury.
Yeung and colleagues
22 originally demonstrated that the
histone deacetylase SIRT1 can interact with RelA to inhibit
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plasmid. OGD stimulated luciferase activity in pSG5 but not in RelA-K310R-expressing cells. Resveratrol (30mM), added after the OGD and maintained for 4h, repressed
luciferase activity in pSG5-cells. Bars are the means±S.E.M. of three separate experiments; *Po0.01, **Po0.05 versus OGD value in pSG5-expressing neurons
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Cell Death and Diseasegene transcription by deacetylating RelA at Lys310, without
modifying the other lysine residue. These results suggested
that acetylated Lys310 might form a platform for the binding of
a bromodomain-containing protein that is required for full
transcriptional activity of RelA.
36 Interestingly, SIRT1 protects
against neurodegeneration, and SIRT1 levels rise rapidly in
various neurotoxic and neurodegenerative conditions; these
results suggest SIRT1 may represent a stress sensor
molecule that is important for the neuroprotective adaptation
response.
37 We checked the effects induced in cortical
neurons by resveratrol, a pharmacological activator of
SIRT1.
22 In line with previous evidence,
37,38 resveratrol
protected neuronal cells in a concentration-dependent man-
ner, even if added after exposure to OGD. This effect
correlated with the capability of the compound to abolish
Lys310 acetylation, in spite of a modest inhibition of RelA
nuclear translocation and a minor reduction in total RelA
acetylation. As a consequence of speciﬁc RelA deacetylation,
resveratrol repressed the acetyl-RelA Lys310-dependent
transcription of Bim promoter during OGD. We cannot rule
out the fact that additional targets of SIRT1 deacetylase
activity, including FOXO3, p53 and peroxisome proliferator,
activated receptor gamma co-activator 1a (PGC-1a) tran-
scription factors,
37,39 as well as mechanism other than SIRT1
activation
38 may contribute to the neuroprotection by resver-
atrol. Nonetheless, the present data are consistent with
the hypothesis that the use of pharmacological agents
modulating SIRT1 activity affects the acetylation status of
RelA protein at Lys310, as well as its pro-apoptotic trans-
activation potential.
The issue of RelA acetylation has been thought to explain
thepro-inﬂammatoryactivityofp50/RelAinimmunecells,
40,41
reactive astrocytes
42 and microglial cells.
23 Here, we demon-
strate that in neuronal cells does the acetylation of RelA
at Lys310 function as an intranuclear molecular switch that
discriminates betweenthe neurotoxic and the neuroprotective
NF-kB pathway in brain ischemia. The acetylation of RelA at
Lys310 may represent a new drugable target to reproduce the
preconditioning-induced activation of NF-kB.
Materials and Methods
Cell culture
Primary cultures of mouse cortical neurons. Cortical neurons were
prepared from 15-day-old embryonic mice, harvested with cesarean section from
anaesthetized pregnant C57Bl/6 dams (Charles River, Italy) and cultured as
previously described.
8 Experiments were carried out at 11 days in vitro (DIV).
SK-N-SH cell culture. The human SK-N-SH neuroblastoma cell line was
purchased fromAmericanTypeCultureCollection(Rockville,MD,USA).Cellswere
grown at 371C in a humidiﬁed atmosphere of 5% CO2, 95% O2 in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Euroclone, Milan, Italy) supplemented with fetal
calf serum, 4mM glutamine and 100U/ml penicillin/streptomicin. The addition of
50mM RA (Sigma, St. Louis, MO, USA) for 10–12 days induced mitotic arrest and
differentiation into a neuronal-like phenotype.
25
Cerebral ischemia models
Transient middle cerebral artery occlusion (MCAO). Procedures
involving animals were approved by the Institutional Animal Care Committee in
compliancewiththeItalianguidelinesforanimalcare(DL116/92)andtheEuropean
Communities Council Directive (86/609/EEC). C57Bl/6 male mice (Harlan, Milan,
Italy) were exposed to IPC and/or transient (20min) MCAO as previously
described.
24ForIPC,mice(n¼9)wereanesthetized,andbilateralcommoncarotid
arteries were occluded (BCCAO) for 5min with microclips. After 24h, mice
underwent 20min MCAO as reported.
24 Parallel groups were subjected to BCCAO
(n¼9) or MCAO (n¼9) alone. Infarcts were measured 3 days later to rule out
transient neuroprotection. Examination of infarct volume was performed in brains
frozeninliquidnitrogentoavoidpost-mortemchanges.Topreparenuclearextracts,
micewerekilledbydecapitation4hafterBCCAO(n¼3),MCAO(n¼3)orBCCAO
and MCAO (IPC) (n¼3).
OGD. Primary cortical neurons at 11 DIV were exposed to OGD as previously
described,
8 for 1 or 3h. Cells recovered for 24h in culture medium and were
typically aerated in the incubator for the evaluation of cell viability. Resveratrol (1, 3
and30mM)(Calbiochem,BeestonNottingham,UK)wasaddedinthepost-ischemic
period. Nuclear proteins were extracted at the end of OGD or after an additional 2h
incubation with resveratrol. SK-N-SH neuronal cells were exposed to 1 to 4h OGD
for analysis of NF-kB in nuclear extracts. Cells were exposed to 15h OGD and
replacedinfreshDMEMwithoutserumfor24hforanalysisofcellviability.Neuronal
injury was evaluated by measuring the amount of LDH (Promega, Madison, WI,
USA) released relative to total releasable LDH.
8
Co-immunoprecipitation and western blot analyses. Nuclear
protein extracts were prepared as previously described
8 from primary cortical
neurons and from differentiated SK-N-SH cells, immediately after OGD exposure or
after an additional time as indicated, or from the cortices of mice exposed to 5min
BCCAO followed by 4h reperfusion, 20min of MCAO followed by 4h reperfusion,
5min BCCAO and 24h later, 20min MCAO (IPC) and 4h reperfusion.
Co-immunoprecipitation studies and immunoblot analyses were carried out as
previously described.
8 In total, 20mg of nuclear extracts were incubated at 41C
overnight with 2mg/ml of goat polyclonal anti-RelA antibody (sc-372G, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and co-immunoprecipitated proteins were
detected by immunoblotting using the following antibodies: rabbit polyclonal
anti-p50 (1:500, ab7971 Abcam, Cambridge, UK), rabbit polyclonal anti-c-Rel
(1:50, sc-71X Santa Cruz Biotechnology), rabbit polyclonal anti-RelA (1:200,
sc-372, Santa Cruz Biotechnology), rabbit polyclonal anti-Acetyl-RelA (Lys310)
(1:500,#3045,CellSignaling,Danvers,MA,USA),rabbitpolyclonalanti-Acetyl-Lys
(1:500, #06-933 Upstate-Millipore, Billerica, MA, USA) and rabbit polyclonal anti-
CBP (1:500,sc-583 Santa Cruz Biotechnology).For immunoblotanalyses, nuclear
proteins (25mg proteins/sample) were resolved by 10% SDS/polyacrylamide gel.
Immunodetection was performed by incubating the membrane overnight at 41C,
with the following primary antibodies: rabbit polyclonal anti-Acetyl-RelA (Lys310)
(1:500, #3045 Cell Signaling), rabbit polyclonal anti-RelA (1:200, sc-372 Santa
Cruz Biotechnology), rabbit polyclonal anti-histone H3 (1:1000, #9715 Cell
Signaling) and rabbit polyclonal anti-C23 nucleolin (1:300, sc-13057 Santa Cruz
Biotechnology).Quantiﬁcationofproteinexpressionwasperformedbydensitometry
analysis of immunoblots, using Gel Pro.3 analysis software (MediaCybernetics,
MD, USA).
NF-jB activation. The binding of mouse p50 and RelA to the NF-kB-binding
consensus sequence was measured in nuclear extracts using the ELISA-based
Mercury TransFactor kit (BD Biosciences, San Jose, CA, USA) as previously
described.
10 Data are expressed as the absorbance difference observed in the
presence of nuclear extracts and that observed in the absence of nuclear extracts.
Expression plasmids and transfections. The wild-type RelA plasmid
8
was used as a template to produce the Lys-to-arginine mutant construct RelA-
K310R using the Quick change site-directed method (Stratagene, La Jolla, CA,
USA), and Pfu DNA Polymerase. The primers sequence synthesized for the
mutagenesiswerethefollowing:RelA-K310Rfor50-AGGACATATGAGACCTTCAG
GAGCATCATGAAGAAGAG-30; RelA-K310R REV 50-CTCTTCTTCATGATGCTCC
TGAAGGTCTCATATGTCCT-30 (nucleotide substitution is in bold). The results of
mutagenesis were conﬁrmed by sequencing clones with the following internal
primer, K310R 50-GCCTGCAGGCTCCTGTGCGT-30. Restriction map analysis was
further carried out to verify construct integrity, and expression was conﬁrmed by
immunoblotting with the anti-RelA antibody in differentiated SH-N-SK cells, using
the following antibodies: rabbit polyclonal anti-RelA (1:200, sc-372, Santa Cruz
Biotechnology) and mouse monoclonal anti-b-tubulin (1:1500, NeoMarkers,
Fremont, CA, USA).
Transfection of differentiated SK-N-SH cells was carried out according to the
manufacturer’s instructions with Lipofectamine 2000 Reagent (LF 2000, Invitrogen
Corp., Carlsbad, CA, USA), as previously described.
8 Cells were transfected with
expressionplasmidsencodingRelA,RelA-K310RoremptyexpressionvectorpSG5
as a negative control, for 24h, before undergoing the OGD experiments.
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Cell Death and DiseaseReporter gene assays. In order to evaluate mouse Bim promoter activity
during OGD, cortical neurons were transfected at 10 DIV using LF 2000 Reagent
with 0.2mg/well of the Bim-pGL3 plasmid and 0.8mg/well of RelA or RelA-K310R
mutant construct or empty expression vector pSG5 as negative control, as
previously described.
8 To normalize the transfection efﬁciency, 0.02mg/well Renilla
luciferase (phRLTK) control plasmid (Promega) was used. After 24h, neurons were
exposed to 3h OGD as described above. At the end of incubation, during the 4h
recovery in Neurobasal medium with 0.4% B27 supplement (Invitrogen Corp.), the
cells expressing pSG5 were treated with resveratrol (30mM). Cells were then
harvested, and ﬁreﬂy and Renilla luciferase were measured by using Dual
Luciferase Reporter Assay (Promega).
Statistics. NF-kB ELISA data were analyzed using one-way analysis of
variance (ANOVA), followed by Dunnett’s post hoc analysis to determine statistical
signiﬁcance. Po0.05 was considered signiﬁcant. Columns represent the
means±S.E.M. of at least four values. Data describing cell survival were
analyzed by Kruskal–Wallis non-parametric ANOVA with adjustment for multiple
comparisons. Data relative to densitometry analyses and luciferase reporter activity
wereanalyzedusingStudent’st-testforindependentdata.Po0.05wasconsidered
as signiﬁcant.
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